DMTX Dimension Therapeutics, Inc.

4.30
-0.1  -2.27%
Previous Close 4.40
Open 4.45
Price To book 1.53
Market Cap 107.68M
Shares 25,043,000
Volume 32,854
Short Ratio 6.53
Av. Daily Volume 94,695

SEC filingsSee all SEC filings

  1. 8-K - Current report 17538835
  2. EFFECT - Notice of Effectiveness 162014760
  3. CORRESP [Cover] - Correspondence
  4. UPLOAD [Cover] - SEC-generated letter
  5. 8-K - Current report 161986065

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated late 2016 - Announced December 13, 2016 that IND submission had been accepted by FDA.
DTX101
Ornithine Transcarbamylase (OTC) Deficiency
Phase 1/2 initial data due January 2017.
DTX101
hemophilia B

Latest News

  1. DIMENSION THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  2. Is Dimension Therapeutics Inc (DMTX) Going to Burn These Hedge Funds?
  3. Dimension Therapeutics Announces FDA Acceptance of Investigational New Drug Application for DTX301 to Treat OTC Deficiency
  4. Dimension Therapeutics Announces Presentation at the 58th American Society of Hematology (ASH) Annual Meeting
  5. Dimension Therapeutics Receives Positive Opinion for European Orphan Drug Designation of DTX401 for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
  6. DIMENSION THERAPEUTICS, INC. Financials
  7. Here’s What We Are Looking For From The Upcoming Dimension Therapeutics Inc (DMTX) Data
  8. ETFs with exposure to Dimension Therapeutics, Inc. : November 14, 2016
  9. Dimension Therapeutics, Inc. :DMTX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 11, 2016
  10. Dimension Therapeutics Reports Recent Corporate Progress and Third Quarter 2016 Financial Results
  11. DIMENSION THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
  12. DIMENSION THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
  13. Dimension Therapeutics Reports Recent Corporate Progress and Third Quarter 2016 Financial Results
  14. Dimension Therapeutics Announces Presentation at the Upcoming 58th American Society of Hematology (ASH) Annual Meeting
  15. Dimension Therapeutics Announces Orphan Drug Designation of DTX401 for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
  16. ETF’s with exposure to Dimension Therapeutics, Inc. : August 24, 2016
  17. Dimension Therapeutics Announces Participation in Two Upcoming Investor Conferences
  18. Dimension Therapeutics, Inc. :DMTX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016
  19. DIMENSION THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  20. Dimension Therapeutics Reports Recent Corporate Progress and Second Quarter 2016 Financial Results

SEC Filings

  1. 8-K - Current report 17538835
  2. EFFECT - Notice of Effectiveness 162014760
  3. CORRESP [Cover] - Correspondence
  4. UPLOAD [Cover] - SEC-generated letter
  5. 8-K - Current report 161986065
  6. S-3 - Registration statement under Securities Act of 1933 161986059
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 161986044
  8. CT ORDER - Confidential treatment order 161871540
  9. 8-K - Current report 161823084
  10. 8-K - Current report 161823078